USANA Health Sciences (NYSE:USNA) updated its third quarter 2021 earnings guidance on Thursday. The company provided EPS guidance of $1.280-$1.330 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.440. The company issued revenue guidance of $265 million-$270 million, compared to the consensus revenue estimate of $303.24 million.USANA Health Sciences also updated its FY 2021 guidance to $5.800-$6.000 EPS.
USNA has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of USANA Health Sciences from a sell rating to a hold rating in a research report on Wednesday, September 29th. Tigress Financial reaffirmed a buy rating and set a $122.00 price objective on shares of USANA Health Sciences in a research report on Friday, October 8th.
USNA traded up $0.21 during midday trading on Thursday, reaching $97.39. 100 shares of the company’s stock were exchanged, compared to its average volume of 88,851. USANA Health Sciences has a 1-year low of $73.00 and a 1-year high of $107.85. The business’s 50-day moving average price is $94.42 and its 200 day moving average price is $98.19. The stock has a market capitalization of $1.95 billion, a PE ratio of 14.66 and a beta of 0.85.
In related news, insider Robert A. Sinnott sold 1,648 shares of the firm’s stock in a transaction dated Monday, August 16th. The stock was sold at an average price of $95.04, for a total transaction of $156,625.92. Following the sale, the insider now directly owns 1,648 shares in the company, valued at approximately $156,625.92. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director John Turman Fleming sold 300 shares of the firm’s stock in a transaction dated Monday, August 30th. The shares were sold at an average price of $97.26, for a total value of $29,178.00. Following the sale, the director now owns 851 shares of the company’s stock, valued at $82,768.26. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 3,435 shares of company stock valued at $331,837. Corporate insiders own 0.21% of the company’s stock.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, Personal Care and Skincare, and All Other. The Essentials Nutritionals category includes vitamin and mineral supplements that provide a foundation of advanced total body nutrition for every age group.
Further Reading: What are the Benefits of Index Funds?
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.